Literature DB >> 21262926

The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.

Dapeng Xu1, Stephen A Allsop, Sam M Witherspoon, Jared L Snider, Jen Jen Yeh, James J Fiordalisi, Catherine D White, Daniel Williams, Adrienne D Cox, Antonio T Baines.   

Abstract

Oncogenic Pim-1 kinase is upregulated in multiple solid cancers, including human pancreatic ductal adenocarcinoma (PDAC), a highly lethal disease with few useful treatment options. Pim-1 is also transcriptionally induced upon oncogenic K-Ras-mediated transformation of the human pancreatic ductal epithelial (HPDE) cell model of PDAC. Given the near ubiquitous presence of mutant K-Ras in PDAC and its critical role in this disease, we wished to study the effects of oncogenic K-Ras signaling on Pim-1 expression, as well as the role of Pim-1 in growth transformation of PDAC cells. Pim-1 protein levels were upregulated in both PDAC cell lines and patient tumor tissues. Furthermore, ectopic oncogenic K-Ras increased Pim-1 expression in human pancreatic nestin-expressing (HPNE) cells, a distinct immortalized cell model of PDAC. Conversely, shRNA-mediated suppression of oncogenic K-Ras decreased Pim-1 protein in PDAC cell lines. These results indicate that oncogenic K-Ras regulates Pim-1 expression. The kinase activity of Pim-1 is constitutively active. Accordingly, shRNA-mediated suppression of Pim-1 in K-Ras-dependent PDAC cell lines decreased Pim-1 activity, as measured by decreased phosphorylation of the pro-apoptotic protein Bad and increased expression of the cyclin-dependent kinase inhibitor p27Kip1. Biological consequences of inhibiting Pim-1 expression included decreases in both anchorage-dependent and -independent cell growth, invasion through Matrigel and radioresistance as measured by standard clonogenic assays. These results indicate that Pim-1 is required for PDAC cell growth, invasion and radioresistance downstream of oncogenic K-Ras. Overall, our studies help to elucidate the role of Pim-1 in PDAC growth transformation and validate Pim-1 kinase as a potential molecular marker for mutated K-Ras activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21262926      PMCID: PMC3066419          DOI: 10.1093/carcin/bgr007

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  43 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.

Authors:  Ambrose R Kidd; Jared L Snider; Timothy D Martin; Sarah F Graboski; Channing J Der; Adrienne D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-07       Impact factor: 7.038

3.  Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.

Authors:  Thomas B Brunner; Keith A Cengel; Stephen M Hahn; Junmin Wu; Douglas L Fraker; W Gillies McKenna; Eric J Bernhard
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

4.  Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase.

Authors:  Kevin C Qian; Lian Wang; Eugene R Hickey; Joey Studts; Kevin Barringer; Charline Peng; Anthony Kronkaitis; Jun Li; Andre White; Sheenah Mische; Bennett Farmer
Journal:  J Biol Chem       Date:  2004-11-03       Impact factor: 5.157

5.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

Authors:  Zuping Xia; Christian Knaak; Jian Ma; Zanna M Beharry; Campbell McInnes; Wenxue Wang; Andrew S Kraft; Charles D Smith
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

Review 6.  Targeting signal transduction in pancreatic cancer treatment.

Authors:  Jen Jen Yeh; Channing J Der
Journal:  Expert Opin Ther Targets       Date:  2007-05       Impact factor: 6.902

7.  Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer.

Authors:  Arthur Y Shaw; Meredith C Henderson; Gary Flynn; Betty Samulitis; Haiyong Han; Steve P Stratton; H-H Sherry Chow; Laurence H Hurley; Robert T Dorr
Journal:  J Pharmacol Exp Ther       Date:  2009-08-05       Impact factor: 4.030

8.  Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.

Authors:  Shannon M Mumenthaler; Patricia Y B Ng; Amanda Hodge; David Bearss; Gregory Berk; Sarath Kanekal; Sanjeev Redkar; Pietro Taverna; David B Agus; Anjali Jain
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

9.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.

Authors:  Lisa S Chen; Sanjeev Redkar; David Bearss; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2009-09-04       Impact factor: 22.113

10.  Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation.

Authors:  Jian Chen; Masanobu Kobayashi; Stephanie Darmanin; Yi Qiao; Christopher Gully; Ruiying Zhao; Satoshi Kondo; Hua Wang; Huamin Wang; Sai-Ching Jim Yeung; Mong-Hong Lee
Journal:  Am J Pathol       Date:  2009-06-15       Impact factor: 4.307

View more
  24 in total

1.  IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines.

Authors:  Katherine M Block; Neale T Hanke; Erin A Maine; Amanda F Baker
Journal:  Pancreas       Date:  2012-07       Impact factor: 3.327

2.  Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.

Authors:  Dapeng Xu; Michael G Cobb; Lily Gavilano; Sam M Witherspoon; Daniel Williams; Catherine D White; Pietro Taverna; Brian K Bednarski; Hong Jin Kim; Albert S Baldwin; Antonio T Baines
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

Review 3.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

4.  Expression of proviral integration site for Moloney murine leukemia virus 1 (Pim-1) is post-transcriptionally regulated by tristetraprolin in cancer cells.

Authors:  Hong Kyeung Kim; Chae Won Kim; Mai-Tram Vo; Hyun Hee Lee; Ji Young Lee; Nal Ae Yoon; Chae Yeong Lee; Chang Hoon Moon; Young Joo Min; Jeong Woo Park; Wha Ja Cho
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

5.  Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.

Authors:  Lisa S Chen; Sanjeev Redkar; Pietro Taverna; Jorge E Cortes; Varsha Gandhi
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

6.  Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

Authors:  Meng Wang; Jing Han; Lynnette Marcar; Josh Black; Qi Liu; Xiangyong Li; Kshithija Nagulapalli; Lecia V Sequist; Raymond H Mak; Cyril H Benes; Theodore S Hong; Kristin Gurtner; Mechthild Krause; Michael Baumann; Jing X Kang; Johnathan R Whetstine; Henning Willers
Journal:  Cancer Res       Date:  2017-02-15       Impact factor: 12.701

7.  The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Authors:  F F Blanco; M Jimbo; J Wulfkuhle; I Gallagher; J Deng; L Enyenihi; N Meisner-Kober; E Londin; I Rigoutsos; J A Sawicki; M V Risbud; A K Witkiewicz; P A McCue; W Jiang; H Rui; C J Yeo; E Petricoin; J M Winter; J R Brody
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 8.  Cell and gene therapy for severe heart failure patients: the time and place for Pim-1 kinase.

Authors:  Sailay Siddiqi; Mark A Sussman
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-08

9.  Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy.

Authors:  Qiang Zhang; Mahaveer S Bhojani; Edgar Ben-Josef; Aaron C Spalding; Rork Kuick; Yi Sun; Meredith A Morgan
Journal:  J Carcinog Mutagen       Date:  2013-08-16

10.  MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1.

Authors:  Xiao-Yu Liu; Zhi-Jian Liu; Hong He; Chen Zhang; Yun-Long Wang
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.